CA3079604A1 - Conformational epitopes in respiratory syncytial virus g protein central conserved region - Google Patents

Conformational epitopes in respiratory syncytial virus g protein central conserved region Download PDF

Info

Publication number
CA3079604A1
CA3079604A1 CA3079604A CA3079604A CA3079604A1 CA 3079604 A1 CA3079604 A1 CA 3079604A1 CA 3079604 A CA3079604 A CA 3079604A CA 3079604 A CA3079604 A CA 3079604A CA 3079604 A1 CA3079604 A1 CA 3079604A1
Authority
CA
Canada
Prior art keywords
seq
rsv
peptide
mutant
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3079604A
Other languages
English (en)
French (fr)
Inventor
Rebecca DUBOIS
Stas FEDECHKIN
Lawrence M. Kauvar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trellis Bioscience Inc
University of California San Diego UCSD
Original Assignee
Trellis Bioscience Inc
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc, University of California San Diego UCSD filed Critical Trellis Bioscience Inc
Publication of CA3079604A1 publication Critical patent/CA3079604A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18533—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3079604A 2017-10-13 2018-10-12 Conformational epitopes in respiratory syncytial virus g protein central conserved region Pending CA3079604A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762572271P 2017-10-13 2017-10-13
US62/572,271 2017-10-13
US201762588022P 2017-11-17 2017-11-17
US62/588,022 2017-11-17
US201862633999P 2018-02-22 2018-02-22
US62/633,999 2018-02-22
PCT/US2018/055711 WO2019075400A1 (en) 2017-10-13 2018-10-12 CONFORMATIONAL EPITOPES IN A CENTRAL PROTECTED REGION OF SYNCYTIAL RESPIRATORY VIRUS PROTEIN G

Publications (1)

Publication Number Publication Date
CA3079604A1 true CA3079604A1 (en) 2019-04-18

Family

ID=66101661

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3079604A Pending CA3079604A1 (en) 2017-10-13 2018-10-12 Conformational epitopes in respiratory syncytial virus g protein central conserved region

Country Status (6)

Country Link
US (2) US11773143B2 (https=)
EP (1) EP3694548A4 (https=)
JP (1) JP7445895B2 (https=)
AU (1) AU2018346960A1 (https=)
CA (1) CA3079604A1 (https=)
WO (1) WO2019075400A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3833677A4 (en) 2018-08-08 2022-04-27 Trellis Bioscience, Inc. IMPROVED RSV PASSIVE AND ACTIVE VACCINES
US12367329B1 (en) * 2024-06-06 2025-07-22 EvolutionaryScale, PBC Protein binder search
CN119479801A (zh) * 2024-11-11 2025-02-18 苏州系统医学研究所 一种针对囊膜病毒表面抗原稳定突变位点的数据预测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
DE60136381D1 (de) * 2000-10-18 2008-12-11 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
BRPI0819210A2 (pt) 2007-10-25 2015-06-23 Trellis Bioscience Inc Anticorpos de proteína g anti-rsv
CN103037898B (zh) * 2010-07-07 2016-06-29 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
EP3408284A4 (en) * 2016-01-28 2019-08-14 The Brigham and Women's Hospital, Inc. DETERMINATION OF AN ANTIBODY AGAINST A PATHOGEN

Also Published As

Publication number Publication date
EP3694548A4 (en) 2021-10-20
US20190135876A1 (en) 2019-05-09
US11773143B2 (en) 2023-10-03
JP7445895B2 (ja) 2024-03-08
AU2018346960A1 (en) 2020-05-28
EP3694548A1 (en) 2020-08-19
JP2020536934A (ja) 2020-12-17
WO2019075400A1 (en) 2019-04-18
US20240150414A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
US20240150414A1 (en) Conformational epitopes in respiratory syncytial virus g protein central conserved region
CN103483421B (zh) 用于治疗hbv感染及相关疾病的多肽及抗体
TWI877396B (zh) 一種抗新型冠狀病毒的雙特異性抗體及其應用
US20240067706A1 (en) Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof
US9902765B2 (en) Antibodies against chikungunya virus and uses thereof
US11834494B2 (en) Antibodies to zika virus and methods of use thereof
Naidoo et al. The potential of nanobodies for COVID-19 diagnostics and therapeutics
CN106459186A (zh) 针对hiv‑1 v1v2 env区域的广谱中和性单克隆抗体
WO2023040835A1 (zh) 一株羊驼源纳米抗体及其应用
Isaacs et al. A nanobody-based therapeutic targeting Nipah virus limits viral escape
US20230374153A1 (en) METHODS OF PREVENTING OR TREATING INFECTION BY RESPIRATORY VIRUSES INCLUDING SARS-CoV-2
WO2023040834A1 (zh) 一株羊驼源纳米抗体及其应用
Zhang et al. A potent neutralizing nanobody targeting a unique epitope on the receptor-binding domain of SARS-CoV-2 spike protein
WO2022210830A1 (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗体
US10766929B2 (en) De novo designed hemagglutinin binding proteins
US12246063B2 (en) Immunogen providing an extended protective lifetime against respiratory syncytial virus (RSV) and vaccines thereof
US20240285753A1 (en) Epitope-scaffold immunogens for pancoronavirus vaccines
US20250179152A1 (en) Sars-cov-2 neutralizing synthetic proteins
Fedechkin Structures Of Respiratory Syncytial Virus G Antigen Bound To Broadly Neutralizing Antibodies For Vaccine And Therapeutic Design
Van Zant et al. SARS-CoV-2 spike protein binding ligands and its application in COVID-19 therapeutics
WO2024061188A1 (zh) 一种冠状病毒多价疫苗及其应用
CN118891272A (zh) SARS-CoV-2刺突蛋白变体、其药物组合物及用途
JP2022542003A (ja) 免疫原
Duyvesteyn et al. OPEN ACCESS llArticle SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses Wanwisa Dejnirattisai, 1, 35 Jiandong Huo, 2, 35 Daming Zhou, 2, 3, 35 Ji rı Zahradnık, 4, 35 Piyada Supasa, 1, 35 Chang Liu, 1, 3, 35